Milestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference
May 31, 2024 08:00 ET
|
Milestone Pharmaceuticals Inc.
MONTREAL and CHARLOTTE, N.C., May 31, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will participate in the Jefferies...
Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™
May 29, 2024 07:00 ET
|
Milestone Pharmaceuticals Inc.
MONTREAL and CHARLOTTE, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of...
Milestone Pharmaceuticals Partners with Arrhythmia Alliance on SVT Awareness
May 22, 2024 08:00 ET
|
Milestone Pharmaceuticals Inc.
MONTREAL and CHARLOTTE, N.C., May 22, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of...
Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
May 13, 2024 07:15 ET
|
Milestone Pharmaceuticals Inc.
– NDA for etripamil in PSVT resubmitted in 1Q 2024– Cash resources as of March 31, 2024 expected to fund operations into 2026– Dialogue with FDA to finalize Phase 3 protocol for etripamil in AFib-RVR...
Milestone® Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024
May 02, 2024 08:00 ET
|
Milestone Pharmaceuticals Inc.
MONTREAL and CHARLOTTE, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of...
Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium
April 17, 2024 08:00 ET
|
Milestone Pharmaceuticals Inc.
MONTREAL and CHARLOTTE, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of...
Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting
April 08, 2024 11:36 ET
|
Milestone Pharmaceuticals Inc.
MONTREAL and CHARLOTTE, N.C., April 08, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of...
Milestone® Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference
April 03, 2024 08:00 ET
|
Milestone Pharmaceuticals Inc.
MONTREAL and CHARLOTTE, N.C., April 03, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will deliver a company...
Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences
April 01, 2024 08:00 ET
|
Milestone Pharmaceuticals Inc.
MONTREAL and CHARLOTTE, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of...
Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia
March 28, 2024 07:00 ET
|
Milestone Pharmaceuticals Inc.
MONTREAL and CHARLOTTE, N.C., March 28, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of...